Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder.

Trial Profile

Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 21 Aug 2015

At a glance

  • Drugs Edivoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Registrational
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Aug 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
    • 14 Aug 2015 Status changed from active not recruiting to completed as per ClinicalTrials.gov record.
    • 17 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top